Canada's GenePOC Eyes 2014 for Point-of-Care MDx System, Group B Strep Test | GenomeWeb

Canadian molecular diagnostics firm GenePOC has completed technical development of its benchtop, point-of-care molecular diagnostic system and disposable test cartridges, and has commenced clinical feasibility studies of the platform, company executives said this week.

In addition, the company hopes to begin clinical trials for its first commercial assay – a molecular test to detect group B streptococcus in pregnant women – by the end of 2013, with the hopes of launching the assay and its system, called GenePOC Diagnostics, by the end of 2014.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.